Genentech's Cancer Drug Avastin Recieves New Label Warning
The FDA noted on its website late Monday that it has included new warnings on Avastin, the blockbuster cancer drug developed and marketed by biotech giant Genentech (DNA).
The new warnings include nasal septum bleeding and brain-capillary leakage as about 7 patients have been afflicted by this side effect.
The company explains that such a side effect is quite rare, only 0.1% of the 60,000 patients using Avastin have reported these symptoms, which are reversible.
_
The FDA noted on its website late Monday that it has included new warnings on Avastin, the blockbuster cancer drug developed and marketed by biotech giant Genentech (DNA).
The new warnings include nasal septum bleeding and brain-capillary leakage as about 7 patients have been afflicted by this side effect.
The company explains that such a side effect is quite rare, only 0.1% of the 60,000 patients using Avastin have reported these symptoms, which are reversible.
_
posted by Nico at
7:44 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home